Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBIMA (Precision-Based Immuno-Molecular Augmentation) is a proprietary, AI-driven bioinformatics and computational platform developed by Neo7Bioscience. Unlike standardized therapies, PBIMA functions as a personalized medicine engine that analyzes patient-specific multi-omic data—including genomic, transcriptomic, and proteomic profiles—to design individualized peptide-based immunotherapeutics. The platform utilizes HLA affinity mapping and molecular pathway analysis to identify unique disease signatures and construct custom peptide sequences tailored to the patient's specific immune architecture. This "N-of-1" approach is used to treat a wide array of conditions including various cancers, autoimmune disorders, neurodegenerative diseases, and chronic infections. The platform also integrates a molecular monitoring component called REViSS for ongoing disease surveillance and therapeutic adjustment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PBIMA.